web analytics
December 5, 2016 / 5 Kislev, 5777

Posts Tagged ‘pharmaceuticals’

Al Asqa Mosque Preacher: Jews Train Doctors to Spread Diseases

Monday, August 3rd, 2015

To paraphrase another hate-filled radical Muslim preacher, Israel’s masochistic side teaches Islamists to spread the disease of hatred.

Sheikh Khaled Al-Mughrabi teaches Islam twice a week in the Al-Aqsa Mosque on the Temple Mount, where Israel has ignored, at least publicly, the increasing takeover by supporters of radical Islamic ideology.

His most recently class taught Muslims that Jews own 95% of the pharmaceutical industry and train doctors to create new diseases so they can spread illness and make more money.

Al-Mughrabi, or his script writer, must be given credit for a creative and healthy – make that unhealthy – imagination.

Palestinian Media Watch translated and published al-Mughrabi’s rant that was telecast on the Al-Msjed Al Aqsa channel last Friday:

Many diseases were created in labs – viruses created by doctors who were bought, trained and taught by the Rothschild family, the Freemasons, the Zionists, or the Jews to create and spread disease so they will be able to sell medicine for it.

According to what is told about the Rothschild family, they own more than half of the world’s wealth… There are approximately 950,000 billion dollars in the world. Out of this amount, 500,000 billion dollars belong to the Rothschild family. The Rothschild family owns the World Bank.

They own about 95% of the world’s pharmaceutical industry. Why do I mention the pharmaceutical industry? Many diseases were created in labs…to create and spread disease so they will be able to sell medicine for it. More than 95% of the pharmaceutical industry and the pharmaceutical trade are owned by the Children of Israel.”

Israeli police finally have had enough of al-Mughrabi and arrested him on Sunday for disseminating hate, according to the Palestinian Authority’s Quds Press, which reported that he” gives religious lessons to children at the mosque.”

Tzvi Ben-Gedalyahu

Another Israel Pharmaceutical Firm Goes to NASDAQ

Wednesday, October 9th, 2013

Kitov Pharmaceuticals accounted it plans to apply for listing on the NASDAQ exchange, joining Israel-based Teva and Kamada that are traded on Wall Street.

Kitov is hoping for approval from the U.S. Food and Drug Administration (FDA) after its Phase III clinical trial of a combination drug for the treatment of hypertension and pain relief.

The drug has a potential market of $10 billion, and the company’s stock in Israel has climbed almost 10-fold this year.

It also is developing a combination drug for the treatment of osteoarthritis, with the risk of hypertension and other side effects associated with current treatments, Globes reported.

Jewish Press News Briefs

Israel Start-Up’s Anti-Obesity Pill Set to Go Big Time

Monday, March 11th, 2013

The Israeli start-up Gelesis is in advanced talks with a large pharmaceutical company to develop its pill that makes fat people feel their stomachs are full, resulting in less food intake and a loss in weight.

The pharma company was not identified by Israel’s Globes business newspaper, which said that Gelesis soon will publish results of a recent clinical trial of the pill.

Instead of asking the US Food and Drug Administration (FDA) to consider the product as a nutritional supplement or medical device, the Israeli company wants to offer it is a medicine to increase its market appeal.

The value of the deal with the foreign pharmaceutical company could reach hundreds of millions of dollars. The unidentified company will invest millions of dollars for developing the pill and will pay royalties on sales, Globes added.

The slim-down pill is made from indigestible edible fiber taken before a meal. The pills, after coming in contact with water, inflate and  make food more viscous, keeping it in the stomach longer, and creating the sense of being sated.

A study of the pill’s effects several years ago showed a high rate of those who said they felt they had enough to eat, while only 16 percent reported they suffered side effects of discomfort, which Gelesis may be able to reduce by changing the dosage for certain individuals.

Obesity is a leading cause of death, and the leading treatment for obesity is through surgery.

The obesity treatment market currently includes various appetite suppressants, but the leading solution for morbid obesity is stomach bypass or reduction surgery. Although other products for filling the stomach are under development, Gelesis’ edge is that its product works with food.

A small number of diet drugs are on the market or are being studied by the FDA, but their success has been limited.

Besides Gelesis, at least one other company, EntroMedics, has developed a system to limit the expansion of the stomach and control hunger sensations. However, clinical trials last month were disappointing.

Tzvi Ben-Gedalyahu

Israeli Pharmaceutical Sales Certified in Europe

Wednesday, October 24th, 2012

The European Parliament has approved a pharmaceutical trade agreement with Israel after two years of attempts by the Palestinian Solidarity Campaign to block the partnership.

The Agreement on Conformity Assessment and Acceptance of Industrial Products (ACAA), simplifying sales of Israeli pharmaceuticals in the European Union, passed Tuesday by 379-230.

The measure recognizes Israeli pharmaceutical standards as equal to those of Europe.  It was approved by the European council in March 2010, but its implementation was thwarted by pro-Palestinian organizations who sought to foil Israel’s entry into the European market.

Malkah Fleisher

Teva Opens Massive Plant in Hungary

Monday, October 15th, 2012

Teva Pharmaceuticals has opened a new $110 million plant in Hungary, set to be one of the largest sterile medicines plants in the world.

The 15,000 square meter plant will work primarily in oncology therapeutics, and will produce 160-200 million units of injectables a year.

Teva has been operating in Hungary since 1993, operating a tablet production facility, an advanced pharmaceutical ingredients manufacturing plant, and now the sterile plant, and employs 3,5000 Hungarians.

Malkah Fleisher

Printed from: http://www.jewishpress.com/news/teva-opens-massive-plant-in-hungary/2012/10/15/

Scan this QR code to visit this page online: